Secondary findings in hereditary breast and ovarian cancer predisposition genes in 5070 Polish non-oncological exomes

Whole-exome sequencing (WES) enables identification of medically actionable hereditary cancer predisposition findings beyond the primary diagnostic indication. We performed a retrospective analysis of 5100 clinical WES tests. After exclusion of 30 oncology-related cases, a non-oncological cohort of 5070 WES tests was used to evaluate pathogenic and likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes. A variant-level dataset comprised 151 unique pathogenic or likely pathogenic variants. The overall detection frequency of pathogenic or likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes was 7.1%. The highest gene-level frequencies were observed for CHEK2 (1.54%), ATM (1.34%), BRCA2 (0.75%), BRCA1 (0.61%) and PALB2 (0.59%). Moderate-penetrance hereditary cancer genes accounted for 3.81% of the cohort, slightly exceeding the frequency observed for high-penetrance hereditary cancer and Lynch syndrome-associated genes (3.33%). Among genes included in the ACMG secondary findings framework, BRCA2, BRCA1, and mismatch repair genes accounted for most secondary findings, whereas PTEN and NF1 findings were predominantly phenotype-driven. Of the pathogenic and likely pathogenic findings, 46.7% occurred in genes included in the ACMG Secondary Findings framework, whereas 53.3% occurred in other hereditary cancer predisposition genes analysed in this study. This distribution reflects the deliberately selective scope of the ACMG SF framework and the broader spectrum of hereditary cancer susceptibility findings that may be encountered in clinical WES.

Authors

Institutions

Publication Details

Journal
European Journal of Human Genetics
Published
2026-11-20
DOI
https://doi.org/10.1038/s41431-026-02270-z
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Secondary findings in hereditary breast and ovarian cancer predisposition genes in 5070 Polish non-oncological exomes

Magdalena Marta Kacprzak, Małgorzata Nowak-Kępczyk, Dominika Szczęśniak, Magdalena Mroczek et al.
2 links
European Journal of Human Genetics
BRCA gene mutations in cancer
article

Secondary findings in hereditary breast and ovarian cancer predisposition genes in 5070 Polish non-oncological exomes

Magdalena Marta Kacprzak, Małgorzata Nowak-Kępczyk, Dominika Szczęśniak, Magdalena Mroczek, Agnieszka Kuźniar, Ewa Czukiewska, Tymoteusz Czukiewski, Jacek Kiś
article en

Abstract

Whole-exome sequencing (WES) enables identification of medically actionable hereditary cancer predisposition findings beyond the primary diagnostic indication. We performed a retrospective analysis of 5100 clinical WES tests. After exclusion of 30 oncology-related cases, a non-oncological cohort of 5070 WES tests was used to evaluate pathogenic and likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes. A variant-level dataset comprised 151 unique pathogenic or likely pathogenic variants. The overall detection frequency of pathogenic or likely pathogenic findings in hereditary breast and/or ovarian cancer predisposition genes was 7.1%. The highest gene-level frequencies were observed for CHEK2 (1.54%), ATM (1.34%), BRCA2 (0.75%), BRCA1 (0.61%) and PALB2 (0.59%). Moderate-penetrance hereditary cancer genes accounted for 3.81% of the cohort, slightly exceeding the frequency observed for high-penetrance hereditary cancer and Lynch syndrome-associated genes (3.33%). Among genes included in the ACMG secondary findings framework, BRCA2, BRCA1, and mismatch repair genes accounted for most secondary findings, whereas PTEN and NF1 findings were predominantly phenotype-driven. Of the pathogenic and likely pathogenic findings, 46.7% occurred in genes included in the ACMG Secondary Findings framework, whereas 53.3% occurred in other hereditary cancer predisposition genes analysed in this study. This distribution reflects the deliberately selective scope of the ACMG SF framework and the broader spectrum of hereditary cancer susceptibility findings that may be encountered in clinical WES.

European Journal of Human Genetics
John Paul II Catholic University of Lublin (PL), Medical University of Lublin (PL), University of Basel (CH), University of Zurich (CH), University Hospital of Basel (CH), University Hospital of Zurich (CH)
Good health and well-being
BRCA gene mutations in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon